While many European startups have seen their private valuations tumble, French insurer Alan has pushed in the opposite direction: a fresh funding round lifts its value to about €5 billion (roughly $5.8 billion), signaling renewed investor appetite for health-tech firms that can expand quickly. The move matters now because it highlights how backers are balancing near-term losses against rapid revenue growth and international rollouts—especially where tech and AI are part of the strategy.
Founded in 2016, Alan has built a digital-first health-insurance platform that combines traditional coverage with telemedicine, claims management and wellness tools. The company says its team now numbers around 740 employees and that its services reach roughly one million people across employees, freelancers and retirees.
New financing of €100 million was led by long-time investor Index Ventures and brought in new backers including Greenoaks, Kaaf and SH, plus high-profile angels such as Shopify founder Tobi Lütke and footballer Antoine Griezmann. Belgian bank-insurer Belfius, a prior strategic partner, also participated.
Wegovy subscription aims to shrink Eli Lilly’s lead: telehealth partners begin rollout
Melania Trump reignites Epstein controversy after efforts to silence it
Alan’s CEO, Jean-Charles Samuelian-Werve, noted the fresh capital will be used to accelerate product development and technology work, with specific attention to AI — he also serves as an adviser and board member at French AI group Mistral AI.
| Metric | Reported value |
|---|---|
| Current valuation | €5 billion (~$5.8 billion) |
| Latest raise | €100 million |
| Annual recurring revenue (2025) | €785 million (~$915 million) |
| 2023 net loss | $61 million |
| 2024 net loss | $56 million |
Alan says its recurring revenue rose sharply year over year—about 53% compared with the end of 2024—and that it has reached operational profitability in France, its largest market. The company declined to release country-level profit figures but emphasized it is “approaching operating break-even” overall.
Growth so far has relied on both private-sector deals and public contracts. A notable new win is a mandate to insure up to 135,000 civil servants and their dependents. International expansion has also continued: Alan operates in Belgium and Spain (where customers include HP and Volkswagen) and has recently started commercial activity in Canada after securing provincial licensing.
The financial picture remains mixed. Alan posted net losses of $61 million in 2023 and $56 million in 2024, but says it reduced losses as a share of revenue by roughly half over the past year. Management is prioritizing global growth and product upgrades over immediate profit: the company is targeting about $1.16 billion in ARR for 2026 rather than pressing for full profitability.
Investors appear willing to accept that trade-off. For backers, the rationale is straightforward: a fast-growing revenue base plus technology-led services can justify patient capital, especially when founders signal a focus on AI-enabled features that could differentiate the product.
- What to watch next: progress toward the $1.16 billion ARR goal and whether Alan can sustain margin improvement while scaling abroad.
- Policy implication: public contracts like the civil-servant deal test Alan’s capacity to manage large, regulated accounts.
- Tech angle: the company’s ties to Mistral AI and stated AI investments suggest future features may lean more heavily on automation and personalized care pathways.
Alan’s update is a snapshot of a broader debate in startup finance today: should founders chase immediate profitability, or keep burning selectively to build market share and product advantage? With this round, Alan’s backers are betting on the latter—at least for now.
